Table 1 Patients’ characteristics

Screened patients

Age, (years)

 Median

67.8

 Range

27–83

 Elderly (≥ 70)

59

Sex

 Male

105 (70)

 Female

45 (30)

ECOG PS

 0–1

114 (76)

 ≥ 2

36 (24)

Primary tumor

 NSCLC

90 (60)

 Melanoma

30 (20)

 Renal cell carcinoma

22 (14.7)

 Others

8 (5.3)

No. of metastases

 ≤ 2

47 (31.4)

 > 2

103 (68.6)

Type of anti-PD-1

 Pembrolizumab

45 (30)

 Nivolumab

105 (70)

Line of immunotherapy

 First

39 (26)

 Non-first

111 (74)

  irAEs of any grade

41 (27.3)

BMI (kg/m²)

 Median (range)

26 (16–45)

 Underweight (BMI ≤ 18.5), no (%)

5 (3.3)

 Normal weight (BMI 18.5 < BMI ≤ 24.9), no (%)

53 (35.3)

 Overweight (25 < BMI ≤ 29.9), no (%)

57 (38)

 Obese (BMI ≥ 30), no (%)

35 (23.4)